Related Experiment Video
Updated: Aug 7, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
[Intravenous fibrinolytic treatment in chronic ischemic heart disease (author's transl)]
Insights
Intravenous streptokinase therapy improved angina pectoris in some chronic ischemic heart disease patients. While overall ischemia markers and left ventricular function remained unchanged, the therapy showed potential benefits by altering blood properties and inhibiting platelet aggregation.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Chronic ischemic heart disease patients often experience persistent angina pectoris and exercise-induced ischemia.
- Intravenous streptokinase therapy has been explored for its potential cardioprotective effects.
Purpose:
- To evaluate the efficacy and safety of intravenous streptokinase therapy in male patients with chronic ischemic coronary heart disease, angina pectoris, and exercise-induced ischemia.
Summary:
- 13 male patients received intravenous streptokinase therapy 18.9 months post-infarction or angina onset.
- Measurements included clinical history, heart volume, exercise-ECG, hemodynamic parameters, and angiography.
- Angina pectoris improved in 5 patients, with no worsening reported. Overall ischemia parameters and left ventricular function (ejection fraction, LVEDP) showed no significant changes.
- Discrete angiographic changes were observed. Therapy-related complications did not occur.
- Improved angina was attributed to altered blood properties and inhibited platelet aggregation.
Impact:
- Suggests potential benefits of intravenous streptokinase for angina pectoris in specific patient subgroups.
- Highlights the need for further investigation in patients with short-lasting or initial angina pectoris.
- Provides insights into the mechanisms of streptokinase action, including blood property modification and antiplatelet effects.
Abstract:
In 13 male patients (mean age 49.1 years) with chronic ischemic coronary heart disease (7 transmural and 2 intramural myocardial infarctions), angina pectoris and signs of ischemia during exercise an intravenous streptokinase therapy was performed. The treatment was installed 18.9 months after infarction or after onset of angina pectoris. Before and after intravenous streptokinase therapy the following parameters were measured: history, heart volume, exercise-ECG, Swan-Ganz pulmonary artery measurements during exercise, aortic and left ventricular pressures, coronary angiography, left ventricular angiography. 1. Angina pectoris disappeared in 1 and became better in 4 patients. In none of the patients angina pectoris became worse. 2. The parameters for ischemia were not changed overall by the therapy. But in single patients signs of exercise-induced ischemia were influenced. 3. Mean values of left ventricular function (EF, LVEDP) were not changed. 4. Angiographic changes were discrete. 5. Complications of therapy and worsening of subjective parameters did not occur. 6. The angina pectoris behaviour in 5 patients (became better) is explained by changes of blood properties. The not-appearance of coronary artery occlusions is explained by the inhibition of platelet aggregation. 7. It is suggested that the effect of intravenous streptokinase therapy should be examined in patients with short-lasting angina pectoris and subgroups, such as initial angina pectoris.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Clot Retraction and Fibrinolysis
Rheumatic Heart Disease III: Medical Management
Venous Thrombosis III: Interprofessional Care

